Brief Summary
This is a first-in-human, Phase I/II, open-label, multi-centre, dosethe amount of medication taken escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in combination with an anti-PD-1 mAb in subjects with solid tumours.
Intervention / Treatment
- Drug: LM-108
- Drug: An Anti-PD-1 Antibodya protein made by the immune system to fight against harmful substances (antigens), such as bacteria or viruses
Inclusion Criteria:
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0-1
- Histological or cytological confirmation of recurrent or refractory advancedat a late stage, far along solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
- At least one measurable disease for expansion cohorts per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
- Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.